透景生命拟取得康录生物控股权 追求协同效应

Group 1 - The company plans to acquire 72.8630% of Wuhan Kanglu Biological Technology Co., Ltd. for a transaction amount of RMB 291 million, which will make Kanglu a subsidiary included in the company's consolidated financial statements [1] - Following the initial acquisition, the company intends to purchase an additional 9.1370% of Kanglu's shares in 2026 and 2027, contingent upon meeting certain preconditions, with a transaction amount of RMB 36.5481 million [1] - Upon completion of all transactions, the company will hold a total of 82.00% of Kanglu's shares [1] Group 2 - Kanglu focuses on the fluorescence in situ hybridization (FISH) and PCR molecular diagnostics fields, aiming for rapid, automated, and intelligent solutions in FISH detection [2] - The company has developed and commercialized rapid FISH reagents and automated detection equipment, possessing proprietary technology for FastProbe rapid FISH probe preparation [2] - The acquisition is expected to create synergies in strategic development, market channels, products, and technology, enhancing the company's overall competitiveness and providing new revenue and profit growth opportunities [2]